retatrutide fda approval date Is Approved? Status and Safety Retatrutide for weight loss: Study

GLP-1

When thyroid function declines, patients commonly experience fatigue, weight gain, cold intolerance, constipation, dry skin, hair loss, and cognitive difficulties

Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022

build your model so you can offer multiple options and handle dose titration and switching

Glucagon-like peptide 1 (GLP-1): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential

Report any new palpitations, excessive sweating, heat intolerance, or anxiety to your provider promptly, as these may signal thyroid imbalance rather than simple medication adjustment